Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
GLP-1 receptor agonists mimic gut hormones to curb appetite and slow digestion, a mechanism driving the success of therapies from Novo Nordisk (Ozempic for diabetes and Wegovy for Lillys oral GLP-1 drug orforglipron achieves 12.4% weight loss in phase 3 trial but trails injectable rivals tirzepatide and retatrutide Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes
Lilly offers a $25/month insured copay coupon for Foundayo
10.1007/s10096-020-03899-4 Eur
Incorporating daily physical activity, eating balanced meals regularly, and keeping blood sugar stable with nutrient-dense snacks can go a long way in supporting energy levels, says Sarah Nash, RD
Wegovy is inducing an average 15% reduction in baseline body weight, roughly twice as much as other types of FDA-approved weight-loss medications, says Wadden Ozempic is the same drug but it has only been FDA-approved for treating diabetes and it comes in a lower dose (the maximum prescribed dose of Ozempic is 2.0 mg)
Three Common Employer Strategies Option 1: Cover GLP-1 Medications Many employers choose to provide coverage because they view obesity as an important chronic health condition
US$ 22.83
US$ 22.18
US$ 22.11
US$ 28.89
